Organization
Blacktown Cancer and Haematology Centre
4 abstracts
Abstract
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).Org: Epworth Medical Centre, New Zealand Clinical Research-Auckland, Rotorua Hospital, Blacktown Cancer and Haematology Centre, Beijing Tsinghua Changgung Hospital,
Abstract
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).Org: Next Oncology Virginia and Virginia Cancer Specialists, Henry Ford Cancer Institute, Detroit, MI, UC Davis Comprehensive Cancer Center, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Henan Cancer Hospital,
Abstract
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.Org: BeiGene USA, Inc., San Mateo, CA, BeiGene (Shanghai) Co., Ltd., UPMC Hillman Cancer Center, Auckland Cancer Trials Centre Governance Group, Harbour Cancer & Wellness,
Abstract
A phase I/II trial of NOX66 in combination with nivolumab in patients (pts) with advanced cancer.Org: University of Sydney Medical School, Blacktown Cancer and Haematology Centre, Sydney Adventist Hospital, Western Sydney University, Liverpool Hospital Anatomical Pathology,